Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
T-PHYL vs AMINOPHYLLIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
T-PHYL is a theophylline derivative that inhibits phosphodiesterase, leading to increased intracellular c AMP levels, resulting in bronchodilation and anti-inflammatory effects. It also antagonizes adenosine receptors.
Non-selective phosphodiesterase inhibitor, increasing intracellular c AMP and c GMP; adenosine receptor antagonist, causing bronchodilation, CNS stimulation, and positive chronotropic/inotropic effects.
Treatment of asthma,Chronic obstructive pulmonary disease (COPD),Apnea of prematurity
Treatment of acute bronchial asthma, reversible bronchospasm associated with chronic bronchitis and emphysema,Neonatal apnea (off-label),Adjunctive therapy in COPD exacerbations
400 mg orally every 6 hours, or 200 mg orally every 4 hours for sustained-release.
Loading dose: 6 mg/kg IV over 30 minutes (if not on theophylline); maintenance: 0.5-0.7 mg/kg/hr IV continuous infusion for adults (non-smoking), higher for smokers (0.7-0.9 mg/kg/hr). Oral: immediate-release 200-400 mg every 6 hours; sustained-release 400-600 mg every 12 hours.
7-9 hours in adults; prolonged in hepatic cirrhosis (up to 30 hours), heart failure, or with CYP1A2 inhibitors
Terminal elimination half-life: 3–12 hours in adults (mean ~6 hours); prolonged in hepatic impairment, heart failure, or COPD (up to 30 hours); shorter in smokers (4–5 hours due to CYP1A2 induction); neonates: 20–40 hours.
Primarily hepatic via cytochrome P450 enzymes, including CYP1A2, CYP2E1, and CYP3A4; also undergoes N-demethylation and oxidation.
Hepatic demethylation and oxidation via cytochrome P450 isoenzymes (CYP1A2, CYP3A4, CYP2E1); approximately 10% excreted unchanged in urine.
Renal (10% unchanged), hepatic metabolism (90%) with metabolites excreted in urine
Renal excretion of unchanged drug accounts for ~10%, with the remainder eliminated as metabolites (caffeine, 3-methylxanthine, 1-methyluric acid, 1,3-dimethyluric acid) via urine; minimal biliary/fecal elimination (<5%).
40% bound, primarily to albumin
~40% bound to plasma proteins (primarily albumin).
0.45-0.6 L/kg, approximating total body water; higher in neonates and patients with obesity
0.5 L/kg (range 0.3–0.7 L/kg); increased in neonates, cirrhosis, and malnutrition; reflects distribution into total body water.
Oral immediate-release: 96-100%; oral sustained-release: 80-90%
Oral (immediate-release): 100% (well absorbed); rectal: ~80% (variable); IV: 100%.
For GFR 10-50 m L/min: administer every 8-12 hours; for GFR <10 m L/min: administer every 12-24 hours.
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: reduce dose by 25% and monitor levels; GFR <10 m L/min: reduce dose by 50% and monitor levels closely.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: reduce dose by 75%.
Child-Pugh A: reduce dose by 50%; Child-Pugh B: reduce dose by 75%; Child-Pugh C: use with extreme caution, reduce dose by 90% or consider alternative.
Starting dose 5 mg/kg/day orally divided every 6 hours; titrate to maximum 10 mg/kg/day.
Loading dose: 5-6 mg/kg IV over 30 minutes (if not on theophylline); maintenance: infants <1 year: 0.4-0.7 mg/kg/hr IV; children 1-9 years: 0.8-1.0 mg/kg/hr IV; children >9 years: 0.6-0.8 mg/kg/hr IV. Oral: immediate-release 5 mg/kg every 6 hours; sustained-release not recommended under 6 years.
Start at lowest effective dose (200 mg every 6 hours) and monitor for toxicity due to reduced clearance.
Reduce maintenance dose by 50-75% compared to younger adults; monitor serum theophylline levels closely; typical starting maintenance: 0.3-0.5 mg/kg/hr IV; avoid doses >400 mg/day oral.
No FDA black box warning is currently required for T-PHYL.
No specific FDA boxed warning for aminophylline; however, theophylline (its active metabolite) has a narrow therapeutic index and requires serum concentration monitoring to avoid toxicity.
Narrow therapeutic index; monitor serum concentrations. Use with caution in patients with cardiac disorders, hepatic impairment, or peptic ulcer disease. Risk of seizures at high doses. Avoid abrupt discontinuation.
Narrow therapeutic index; monitor serum concentrations (target 10-20 mcg/m L); caution in patients with peptic ulcer, hyperthyroidism, seizure disorders, cardiac arrhythmias; use with drugs that affect CYP1A2 (e.g., cimetidine, fluoroquinolones, fluvoxamine) or induce metabolism (e.g., smoking, rifampin, phenytoin).
Hypersensitivity to theophylline or any component of the formulation, concomitant use with ephedrine in children.
Hypersensitivity to aminophylline, theophylline, or ethylenediamine; active peptic ulcer disease; uncontrolled seizure disorders; severe cardiac arrhythmias (unless patient is undergoing monitored treatment).
High-protein foods reduce theophylline clearance; high-carbohydrate foods increase clearance. Avoid charcoal-broiled meats and caffeine-containing products (coffee, tea, cola) as they may increase toxicity. Consistency in diet is important to maintain stable serum levels.
High-fat meals can delay absorption of aminophylline. Avoid charred meat and foods containing large amounts of caffeine. Cruciferous vegetables (broccoli, brussels sprouts) may increase metabolism. Maintain consistent dietary intake of protein and carbohydrates as changes can affect theophylline clearance.
First trimester: Possible increase in congenital malformations (e.g., cardiovascular, neural tube defects) based on animal studies and limited human data. Second/third trimester: Risk of fetal tachycardia, irritability, and neonatal withdrawal with chronic use.
Aminophylline, a theophylline salt, is not teratogenic in humans. First trimester: No increased risk of major malformations. Second trimester: No specific fetal risks; maternal asthma control benefits outweigh risks. Third trimester: Risk of neonatal apnea, irritability, and tachycardia if maternal levels are high; avoid toxic levels.
Excreted into breast milk in low amounts (M/P ratio ~0.3-0.5). Use with caution; monitor infant for irritability or poor feeding.
Aminophylline is excreted into breast milk; the M/P ratio (milk-to-plasma ratio) is approximately 0.6-0.8. Infant exposure is low (about 1-10% of maternal weight-adjusted dose). Use with caution; monitor infant for irritability and sleep disturbance. Generally considered compatible with breastfeeding.
Increased clearance and volume of distribution in pregnancy may require dose increase by 30-50% to maintain therapeutic levels. Monitor serum concentrations closely.
Pregnancy reduces theophylline clearance by 30-50% due to decreased hepatic metabolism and increased volume of distribution. Dose adjustments may be needed: reduce dose by 30% in the third trimester or monitor serum concentrations closely to maintain therapeutic levels (5-15 mcg/m L). Postpartum, clearance returns to prepregnancy levels within 4-6 weeks; readjust accordingly.
T-PHYL (theophylline) requires therapeutic drug monitoring to maintain serum concentrations between 5-15 mcg/m L; levels >20 mcg/m L increase toxicity risk. Cigarette smoking induces its metabolism, requiring dose adjustments. Use with caution in patients with CHF, hepatic impairment, or fever, as clearance decreases. Avoid concurrent use of ciprofloxacin, cimetidine, or macrolides which can elevate levels.
Aminophylline is a bronchodilator composed of theophylline and ethylenediamine. The ethylenediamine component can cause hypersensitivity reactions. Monitor theophylline serum levels (target 10-20 mcg/m L). Use with caution in patients with cardiac arrhythmias, seizures, or peptic ulcer disease. Avoid in patients with porphyria. Cimetidine, ciprofloxacin, and macrolides can increase theophylline levels. Smoking induces metabolism, requiring higher doses.
Take exactly as prescribed; do not change dose without consulting your doctor.,Avoid smoking and alcohol; these can alter theophylline levels in your blood.,Report symptoms of toxicity such as nausea, vomiting, insomnia, tremors, or rapid heartbeat.,Do not take over-the-counter medications unless approved by your doctor.,Maintain consistent dietary habits; avoid high-protein or high-carbohydrate diets that affect clearance.
Take this medication exactly as prescribed, with or without food.,Do not crush or chew extended-release formulations.,Avoid consuming large amounts of caffeine (coffee, tea, chocolate, energy drinks) as it may increase side effects.,Report symptoms such as rapid heart rate, persistent nausea/vomiting, insomnia, or seizures immediately.,Do not stop abruptly without consulting your doctor.,Keep a regular dosing schedule to maintain consistent blood levels.
No interactions on record
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about T-PHYL vs AMINOPHYLLIN, answered by our medical review team.
T-PHYL is a Xanthine bronchodilator that works by T-PHYL is a theophylline derivative that inhibits phosphodiesterase, leading to increased intracellular c AMP levels, resulting in bronchodilation and anti-inflammatory effects. It also antagonizes adenosine receptors.. AMINOPHYLLIN is a Xanthine Bronchodilator that works by Non-selective phosphodiesterase inhibitor, increasing intracellular c AMP and c GMP; adenosine receptor antagonist, causing bronchodilation, CNS stimulation, and positive chronotropic/inotropic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between T-PHYL and AMINOPHYLLIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of T-PHYL is: 400 mg orally every 6 hours, or 200 mg orally every 4 hours for sustained-release.. The standard adult dose of AMINOPHYLLIN is: Loading dose: 6 mg/kg IV over 30 minutes (if not on theophylline); maintenance: 0.5-0.7 mg/kg/hr IV continuous infusion for adults (non-smoking), higher for smokers (0.7-0.9 mg/kg/hr). Oral: immediate-release 200-400 mg every 6 hours; sustained-release 400-600 mg every 12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between T-PHYL and AMINOPHYLLIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. T-PHYL is classified as Category C. First trimester: Possible increase in congenital malformations (e.g., cardiovascular, neural tube defects) based on animal studies and limited human data. Second/third trimester: R. AMINOPHYLLIN is classified as Category C. Aminophylline, a theophylline salt, is not teratogenic in humans. First trimester: No increased risk of major malformations. Second trimester: No specific fetal risks; maternal ast. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.